Characteristics Associated With Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence
| Autor: | Deborah L. Myers, Yuko M. Komesu, Michael E. Albo, Stephen W. Erickson, Holly E. Richter, John Eric Jelovsek, W.T. Gregory, Cindy L. Amundsen, Dennis Wallace, Christopher Chermansky, Heidi S. Harvie |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Urology Lumbosacral Plexus 030232 urology & nephrology Urinary incontinence Comorbidity Injections Intramuscular 03 medical and health sciences 0302 clinical medicine Patient satisfaction Quality of life Internal medicine medicine Humans Botulinum Toxins Type A Aged 030219 obstetrics & reproductive medicine Urinary bladder business.industry Age Factors Obstetrics and Gynecology Urinary Incontinence Urge General Medicine Middle Aged medicine.disease Botulinum toxin Lumbosacral plexus Treatment Outcome medicine.anatomical_structure Overactive bladder Patient Satisfaction Quality of Life Transcutaneous Electric Nerve Stimulation Female medicine.symptom business medicine.drug |
| Zdroj: | Obstetrical & Gynecological Survey. 72:709-711 |
| ISSN: | 1533-9866 0029-7828 |
| Popis: | We sought to identify clinical and demographic characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation therapies.We analyzed data from the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation versus BoTulinum Toxin Assessment) trial. Baseline participant characteristics and clinical variables were associated with 2 definitions of treatment response, including 1) a reduction in mean daily urgency incontinence episodes during 6 months and 2) a 50% or greater decrease in urgency incontinence episodes across 6 months. The OAB-S (Overactive Bladder-Satisfaction) questionnaire was used to assess satisfaction.A greater reduction in mean daily urgency incontinence episodes was associated with higher HUI-3 (Health Utility Index-3) scores in the onabotulinumtoxinA group and higher baseline incontinence episodes (each p0.001) in the 2 groups. Increased age was associated with a lesser decrease in incontinence episodes in the 2 groups (p0.001). Increasing body mass index (adjusted OR 0.82/5 points, 95% CI 0.70-0.96) was associated with reduced achievement of a 50% or greater decrease in incontinence episodes after each treatment. Greater age (adjusted OR 0.44/10 years, 95% CI 0.30-0.65) and a higher functional comorbidity index (adjusted OR 0.84/1 point, 95% CI 0.71-0.99) were associated with reduced achievement of a 50% or greater decrease in urgency incontinence episodes in the onabotulinumtoxinA group only (p0.001 and 0.041, respectively). In the onabotulinumtoxinA group increased satisfaction was noted with higher HUI-3 score (p = 0.002) but there was less satisfaction with higher age (p = 0.001).Older women with multiple comorbidities, and decreased functional and health related quality of life had decreased treatment response and satisfaction with onabotulinumtoxinA compared to sacral neuromodulation for refractory urgency incontinence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|